Sophia Genetics, a Switzerland-based clinical genomics technology provider that counts telecommunications firm Swisscom as an investor, completed a $30m series D round led by venture capital firm Balderton Capital yesterday.
The round included VC firm 360º Capital Partners, VC fund Invoke Capital and Alychlo, the investment vehicle for pharmaceutical entrepreneur Marc Coucke. It increased Sophia’s overall funding to approximately $62m.
Sophia has created a clinical genomics analytics platform called Sophia AI that helps physicians diagnose and treat patients more effectively. Users also share information with each other through the company’s network.
The company will use the capital for recruitment and product development as it looks to expand adoption of clinical genomics testing across hospitals.
Jurgi Camblong, co-founder and CEO of Sophia Genetics, said: “Since inception, our vision has been to develop innovative technological solutions to help patients, equally wherever they live.
“Sophia acts as a real disruptor by breaking down the information silos in healthcare, meaning that the information from a patient in London or Paris can for instance help better diagnose and treat a patient in Lagos or Rio.”
Swisscom invested in Sophia through a $13.75m series B round in 2014 that was led by Invoke Capital and backed by VC firm Endeavour Vision. Sophia subsequently raised $15m in a series C led by Marc Coucke late the following year.